Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on ADC Therapeutics. The associated price target remains the same with $7.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors surrounding the promising results from ADC Therapeutics’ LOTIS-7 trial. The trial, which investigates the use of ZYNLONTA in combination with glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), has shown impressive outcomes. The combination therapy achieved a high overall response rate (ORR) of 89.8%, with a complete response (CR) rate of 77.6%, which surpasses many competing treatments in the second-line DLBCL space.
Furthermore, the trial results indicate that the higher dose of 150µg/kg not only maintains efficacy but also offers a better tolerability profile compared to the 120µg/kg dose. Despite potential competition from other treatments being evaluated in different trials, the current data positions ZYNLONTA + glofitamab as a strong contender in the market. These positive clinical outcomes and the potential for market impact underpin Burns’s decision to maintain a Buy rating on ADC Therapeutics’ stock.